ES2093674T3 - Polipeptido capaz de interaccionar con trombina. - Google Patents

Polipeptido capaz de interaccionar con trombina.

Info

Publication number
ES2093674T3
ES2093674T3 ES91202009T ES91202009T ES2093674T3 ES 2093674 T3 ES2093674 T3 ES 2093674T3 ES 91202009 T ES91202009 T ES 91202009T ES 91202009 T ES91202009 T ES 91202009T ES 2093674 T3 ES2093674 T3 ES 2093674T3
Authority
ES
Spain
Prior art keywords
gla
glu
asp
amino acid
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91202009T
Other languages
English (en)
Inventor
Michitaka Zushi
Komakazu Gomi
Shuji Yamamoto
Koji Suzuki
Akio Matsuda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Kasei Corp
Asahi Chemical Industry Co Ltd
Original Assignee
Asahi Chemical Industry Co Ltd
Asahi Kasei Kogyo KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Chemical Industry Co Ltd, Asahi Kasei Kogyo KK filed Critical Asahi Chemical Industry Co Ltd
Application granted granted Critical
Publication of ES2093674T3 publication Critical patent/ES2093674T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/7455—Thrombomodulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE EXPONE UN POLIPEPTIDO SUSTANCIALMENTE PURO PROVISTO DE UNA SECUENCIA AMINOACIDA ESPECIFICA QUE CONTIENE (A) UN RESIDUO AMINOACIDO SELECCIONADO DEL GRUPO QUE CONSTA DE ASP, GLU Y GLA DONDE GLA REPRESENTA UN RESIDUO DE ACIDO Y-CARBOXIGLUTAMICO O (B) UN RESIDUO PEPTIDO O POLIPEPTIDO QUE CONSTA AL MENOS DE DOS RESIDUOS AMINOACIDOS SELECCIONADOS ENTRE ASP, GLU, Y GLA SIENDO LOS DOS RESIDUOS IGUALES O COMBINACIONES DE ASP, GLU Y GLA. EL POLIPEPTIDO ES CAPAZ DE INTERACTUAR CON LA TROMBINA PARA FORMAR UNA UNION, PARA EXHIBIR UNA ACTIVIDAD INHIBIDORA DE LA COAGULACION DE LA SANGRE Y LA AGREGACION PLAQUETARIA POR LA TROMBINA Y/O UNA ACTIVIDAD PARA PROMOVER LA ACTIVACION DE LA PROTEINA C CATALIZADA POR LA TROMBINA. ESTE NUEVO POLIPEPTIDO TIENE UN PESO MOLECULAR BAJO DE FORMA QUE ES IDONEO PARA ADMINISTRACION ORAL O NASAL.
ES91202009T 1990-08-03 1991-08-05 Polipeptido capaz de interaccionar con trombina. Expired - Lifetime ES2093674T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20497890 1990-08-03

Publications (1)

Publication Number Publication Date
ES2093674T3 true ES2093674T3 (es) 1997-01-01

Family

ID=16499445

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91202009T Expired - Lifetime ES2093674T3 (es) 1990-08-03 1991-08-05 Polipeptido capaz de interaccionar con trombina.

Country Status (9)

Country Link
US (1) US5574007A (es)
EP (1) EP0474273B1 (es)
KR (1) KR930008093B1 (es)
AT (1) ATE145241T1 (es)
AU (1) AU632958B2 (es)
CA (1) CA2048425C (es)
DE (1) DE69123106T2 (es)
ES (1) ES2093674T3 (es)
HK (1) HK1000968A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063763A (en) * 1989-04-28 2000-05-16 Schering Aktiengesellschaft Protease-resistant thrombomodulin analogs
US5780303A (en) * 1990-04-06 1998-07-14 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5672585A (en) * 1990-04-06 1997-09-30 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US6521594B1 (en) 1990-04-06 2003-02-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US6017877A (en) * 1990-04-06 2000-01-25 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5916874A (en) * 1994-04-20 1999-06-29 Asahi Kasei Kogyo Kabushiki Kaisha Method for treating liver injury
CA2292759A1 (en) * 1997-06-05 1998-12-10 Abbott Laboratories Reagents and methods useful for detecting diseases of the urinary tract
WO2003033515A1 (en) * 2001-10-15 2003-04-24 Corixa Corporation Compositions and methods for the therapy and diagnosis of acne vulgaris
JP4340540B2 (ja) * 2002-01-18 2009-10-07 旭化成ファーマ株式会社 可溶性トロンボモジュリン高濃度含有製剤
US6706068B2 (en) 2002-04-23 2004-03-16 Bret A. Ferree Artificial disc replacements with natural kinematics
US7579000B2 (en) 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
CN100412090C (zh) * 2002-05-01 2008-08-20 舍林股份公司 作为抗凝剂的新的靶向组织因子的血栓调节蛋白融合蛋白
MX2009003384A (es) * 2006-10-06 2009-04-08 Asahi Kasei Pharma Corp Agente terapeutico y/o de mejoramiento para la coagulacion intravascular diseminada.
CA2681294C (en) 2007-03-23 2014-05-06 Asahi Kasei Pharma Corporation Method for producing high-purity soluble thrombomodulin
JP2011178687A (ja) * 2010-02-26 2011-09-15 Kochi Univ 造血細胞移植に伴う疼痛の予防および／または治療剤
NZ602852A (en) 2010-04-30 2014-03-28 Asahi Kasei Pharma Corp Highly-purified soluble thrombomodulin and method for producing same
PT2781221T (pt) 2011-11-15 2020-06-01 Asahi Kasei Pharma Corp Medicamento para tratamento e/ou melhoria de sepsia
BR112021007460A2 (pt) 2018-10-22 2021-11-03 Asahi Kasei Pharma Corp Medicamento para tratamento terapêutico e/ou melhora de um paciente com sepse
CN112608965B (zh) * 2021-01-15 2022-08-05 华东理工大学 利用深海链霉菌生产怡莱霉素e的培养基及其制备方法
CN113429459B (zh) * 2021-06-16 2022-07-26 昆明医科大学第一附属医院 一种抗血小板多肽及其药物组合物与其应用
AU2023230867A1 (en) * 2022-01-07 2024-06-06 Regents Of The University Of Minnesota Hemostatic composition containing recombinant human clotting factors, and method of producing
CN120365400B (zh) * 2025-06-26 2025-10-31 山东大学 一种东亚钳蝎来源多肽及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0312598B1 (en) * 1987-01-08 1999-05-26 Asahi Kasei Kogyo Kabushiki Kaisha Peptide functioning to accelerate activation of protein c with thrombin
DK299087D0 (da) * 1987-06-12 1987-06-12 Novo Industri As Proteins and derivatives thereof
WO1991004276A1 (en) * 1989-09-25 1991-04-04 Asahi Kasei Kogyo Kabushiki Kaisha Isolated, physiologically active human thrombomodulin polypeptide

Also Published As

Publication number Publication date
DE69123106T2 (de) 1997-04-10
KR920004419A (ko) 1992-03-27
CA2048425C (en) 1998-04-21
HK1000968A1 (en) 1998-05-15
EP0474273A2 (en) 1992-03-11
CA2048425A1 (en) 1992-02-04
ATE145241T1 (de) 1996-11-15
DE69123106D1 (de) 1996-12-19
US5574007A (en) 1996-11-12
AU632958B2 (en) 1993-01-14
EP0474273A3 (en) 1992-04-08
KR930008093B1 (ko) 1993-08-25
EP0474273B1 (en) 1996-11-13

Similar Documents

Publication Publication Date Title
DK0409472T3 (da) Knoglemorfogenetisk protein
DK552684D0 (da) Desulfatohirudiner samt deres fremstilling og anvendelse
AU632958B2 (en) A polypeptide capable of interacting with thrombin
JO1425B1 (en) New vehicles
FI861598A0 (fi) Expression av faktorernas vii och ix aktivitet i daeggdjursceller.
DK288183D0 (da) Fremgangsmade til fremstilling af et oligonucleotidt terapeutisk middel
ES2059547T3 (es) Expresion y secrecion mejoradas de proteinas heterologas en levadura, empleando secuencia conductora de factor alfa truncado.
DE69805772D1 (de) Stabilisierte mischung auf fibrinogenbasis
RU95115239A (ru) Аналог эритропоэтина
ATE148113T1 (de) Retrovirale protease inhibitoren, enthaltend cyclische sulfone
ES2070145T3 (es) Extraccion y purificacion de un principio anticoagulante de la sanguijuela sudamericana, haementeria ghilianii.
DK165988C (da) Modificerede egliner b og c, deres anvendelse som proteaseinhibitorer, fremgangsmaade til fremstilling deraf samt farmaceutiske praeparater indeholdende de modificerede egliner b og c
JPS6485096A (en) Hybrid human protein c and biotechnological synthesis thereof
ES2052916T3 (es) Factor inhibidor del factor xa bovino y composiciones farmaceuticas que lo contienen.
ES2072251T3 (es) Composiciones y metodos para la sintesis y ensayo de enquefalinasa.
DE68910973D1 (de) Arzneimittelzusammensetzung, enthaltend deoxyribonukleoside für heilung von wunden.
ATE63750T1 (de) Peptid, dessen herstellung und benutzung.
FI812044L (fi) Anvaendning av peptider som laekemedel och nya peptider
ES2170747T3 (es) Analogos superiores de trombomodulina para uso farmaceutico.
FI972170A7 (fi) Peptidejä, jotka kykenevät sitoutumaan GAP-proteiinin SH3-domeeniin, n äitä peptidejä koodittavia nukleotidisekvenssejä, niiden valmistus ja käyttö
SE8405588D0 (sv) New compounds
ES548594A0 (es) Un procedimiento para la preparacion de composiciones de un acido amino hidrocarbil sulfonico n-acilado o una sal del mismo.
ES2060134T3 (es) Inhibidor de tejido de metaloproteasas (timp-2).
ES2059801T3 (es) Nuevas linfoquinas, secuencias de adn que codifican para estas linfoquinas, y composiciones farmaceuticas conteniendo estas linfoquinas.
SE9000793L (sv) Sdk-peptider,foerfarande foer framstaellning daerav och terapeutiska kompositioner innehaallande dem

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 474273

Country of ref document: ES